On May 19, 2023 Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, reported that Eric Crombez, M.D., the company’s chief medical officer, will present at the 2023 Barclays – Gene Editing & Gene Therapy Summit on Wednesday, May 24, 2023, at 8:50 a.m. ET (Press release, Ultragenyx Pharmaceutical, MAY 19, 2023, View Source [SID1234631884]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live and archived webcast of the panel will be accessible from the company’s website at View Source